ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0127

Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease

Wenying Liang1, Qinmengge Li2, Jacqueline Madison1, Ran Jing1, Emily Chong1, Yiran Shen1, Rachael Bogle3, Srilakshmi Yalavarthi1, Cyrus Sarosh4, Ajay Tambralli1, Yu (Ray) Zuo1, Johann Gudjonsson1, Hui Shi5, Pei-Suen Tsou1, Alex Tsoi3 and Jason S. Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ypsilanti, MI, 3University of Michigan, Holland, OH, 4University of Michigan, Temperance, MI, 5Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, Bioinformatics, Inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Some of the rarer manifestations of antiphospholipid syndrome (APS), such as cardiac valve disease, remain poorly understood at the molecular level. A previous study profiling skin biopsies from a few patients with marked livedo racemosa preliminarily identified the endothelial cell (EC) Hippo-YAP1-CCN2 axis as a key player in APS vasculopathy. Here, we expanded dermal single-cell profiling to include 30 individuals with primary APS, with the goal of identifying unique tissue signatures associated with some of the more poorly understood features of APS, including cardiac valve disease and nephropathy. In this abstract, we focused on the ligand-receptor pairs predicted to be driving cellular communication in the dermis of patients with a history of cardiac valve disease.

Methods: Single-cell RNA sequencing was used to characterize upper-thigh skin biopsies (epidermis removed) from 30 patients with primary APS (including a subset of eight patients with confirmed valve disease) and 14 healthy controls. Cell-cell interaction analysis was performed using CellPhoneDB to identify enriched (i.e., highly correlated) ligand-receptor pairs between ECs and other potentially interacting cell types. Differential expression and pathway enrichment were evaluated using g:Profiler. Associations with a history of valve disease were tested via logistic regression.

Results: Thirteen cell types were detected within the dermis, with endothelial cells representing 18% of the population in primary APS patients, compared with 16% in controls (p< 0.001). In patients with valve disease (n=8), versus those without (n=22), endothelial cells showed a markedly increased potential for interactions with myeloid cells, smooth muscle cells, and fibroblasts, amongst others (Figure 1). For myeloid cells, highlighted interactions between EC ligands and myeloid cell receptors included CCL23-CCR1, ICAM2-CD209, JAG2-NOTCH1, and DLL1-NOTCH1, with the potential to support inflammatory signaling, leukocyte adhesion, and immune activation. Featured EC interactions with smooth muscle included ANGPT2-TIE2, EDN1-EDNRA, JAG2-NOTCH3, and EFNB1-EPHB6, suggesting increased vascular constriction and remodeling. Notable ligand-receptor interactions between endothelial cells and fibroblasts included PDGFB-PDGFRA, CCL2-CCR2, FN1-ITGA5, and WNT2B-SFRP2, emphasizing fibroblast activation and extracellular matrix (ECM) transformation. Finally, pathway analysis underscored the potential for more leukocyte adhesion, angiogenesis, and ECM remodeling in the tissues of APS patients with a history of valve pathology.

Conclusion: Our findings reveal that endothelial cells of patients with a history of valve disease have significant potential—through their production of chemokines, cell adhesion molecules, and ECM-interacting molecules—to engage in proinflammatory and profibrotic interactions with myeloid cells, smooth muscle cells, and fibroblasts. The identified interactions and pathways provide a roadmap for future research into the valvular pathology that causes significant morbidity for some patients living with APS.

Supporting image 1Figure 1: Dermal ligand-receptor analysis of patients with valve disease. Potentially interacting ligands (x-axis) and receptors (y-axis) were compared between APS patients with a history of valve disease (n=8, right panel) and those without (n=22, left panel). The analysis used CellPhoneDB to identify enriched (i.e., highly correlated) ligand-receptor pairs between dermal cell types. Associations with a history of valve disease were tested via logistic regression.


Disclosures: W. Liang: None; Q. Li: None; J. Madison: None; R. Jing: None; E. Chong: None; Y. Shen: None; R. Bogle: None; S. Yalavarthi: None; C. Sarosh: None; A. Tambralli: None; Y. Zuo: None; J. Gudjonsson: None; H. Shi: None; P. Tsou: None; A. Tsoi: Galderma, 5, Johnson and Johnson, 5; J. Knight: BioCryst, 2, Ouro Medicines, 2, Roche, 2, Roivant Sciences, 2, Visterra, 2.

To cite this abstract in AMA style:

Liang W, Li Q, Madison J, Jing R, Chong E, Shen Y, Bogle R, Yalavarthi S, Sarosh C, Tambralli A, Zuo Y, Gudjonsson J, Shi H, Tsou P, Tsoi A, Knight J. Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/single-cell-profiling-of-dermal-endothelial-cells-reveals-potential-cell-cell-interactions-in-patients-with-aps-and-a-history-of-cardiac-valve-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-cell-profiling-of-dermal-endothelial-cells-reveals-potential-cell-cell-interactions-in-patients-with-aps-and-a-history-of-cardiac-valve-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology